Name

DATE

Alternate names

None

Primary Site

None

Histology

None

Radiation

None

Remarks

None

Drugs for DATE

Name

Alternate Names

Dom-Etoposide
Epipodophyllotoxin derivative
Epipodophyllotoxin ethylidene gluco-pyranoside
Eposine
Ethylidene-Lignan P
Etopophos
Podophyllotoxin derivative
Vepesid
VP 16-213
VP-16
VP-16213
Toposar

Abbreviations

EPEG
VP-16
VP-16-213

Category

Chemotherapy

Subcategory

Epipodophyllotoxin, topoisomerase II inhibitor
Plant alkaloid

NSC Number

141540

Primary Site

Gastric cancer
Hodgkins lymphoma
Lung cancer (NSCLC, SCLC)
Non-Hodgkin lymphoma
testicular cancer (Germ cell tumors)

Histology

None

Remarks

Plant alkaloid. FDA approved use on small-cell lung cancer, testicular cancer.

Coding

This drug should be coded

Name

Alternate Names

11C topotecan
Hycamtin
SKF-104864
Topotecan Hydrochloride

Abbreviations

SKFS

Category

Chemotherapy

Subcategory

Topoisomerase inhibitor

NSC Number

609699

Primary Site

cervix
Colorectal
leukemia
lung
ovarian cancer
small cell lung

Histology

None

Remarks

Phase II (colorectal, NSCLC) Phase II/III SCLC Phase III MDS, ovarian Topoisomerase I inhibitor. FDA approved use on small cell lung cancer and ovarian cancer. GlaxoSmithKline.

Coding

This drug should be coded

Name

Alternate Names

Acetyladriamycin
Cerubidine
Dauno-blastin
Daunomycin
Daunomycin-HCl
Daunorubicin
Daunorubicine
FI-6339
Leuk-aemomycin C
NDC-0082-4155
RP-13057
Rubidomycin
Rubidomycin HCl
Rubomycin C

Abbreviations

Daun
Dauno
DNM
DNR
DRB

Category

Chemotherapy

Subcategory

Antitumor antibiotic

NSC Number

082151
82151

Primary Site

Leukemia

Histology

None

Remarks

FDA approved use on ALL and ANLL; antitumor antibiotic

Coding

This drug should be coded

Name

Alternate Names

AC-1075
Alexan
Ara-cytidine
Arabinocytidine
Arabinosylcytosine
Beta-Arabinosylcytosine
Cytarabin
Cytarabine
Cytarabinoside
Cytosar
Cytosar-U
Cytosine Arabinoside
Cytosine arabinoside hydrochloride
Spongocytidine HCL
Tarabine
Tarabine PFS
U-19920
U-19920A
WR-28453

Abbreviations

ara-C
CA
HDA
HDARA-C

Category

Chemotherapy

Subcategory

Antimetabolite

NSC Number

063878
63878

Primary Site

ALL
AML
CML
head and neck
Hodgkin's disease
leukemia
Meningeal leukemia
NHL

Histology

None

Remarks

Antineoplastic agent; antimetabolite. FDA approved uses on Hodgkin's disease, leukemia; under investigation for Rx of Progressive Multifocal Leukoencephalopathy (PML)

Coding

This drug should be coded
Glossary